OPTEY (OPTEY)
Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Peers in Healthcare
OPTEY has no peer companies in this window.
Recent press releases
OPTEY has not issued a press release in this window.
SEC filings
All filings →OPTEY has not filed an SEC document in this window.
Insider trades
All insider trades →OPTEY has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at OPTEY
All people →No officers or directors have been indexed for OPTEY.